Although the exact mechanism by which CTLA4 variations affect MS is unclear, it is hypothesized that abnormal CTLA4 signaling disrupts the balance between effector T cells and Tregs in MS, leading to intensified immune responses and increased inflammation [173]. Here, CTLA4 is linked to myeloid sarcoma.